Robotic radical hysterectomy for stage 1B1 cervical cancer: A case series of survival outcomes from a leading UK cancer centre

Abstract

BackgroundWe present the largest UK single institute robotic radical hysterectomy (RRH) case series for the management of cervical cancer (CC).MethodsData were collected on women who had a RRH as primary treatment for stage 1b1 CC between December 2009 and December 2018.ResultsNinty women had a robotic hysterectomy. Five‐year follow‐up data were available for 30%. The disease‐free survival at 5 years was 89.6%. Overall survival at 3 and 5 years for death from any cause was 96.1% and 91.4%, respectively. The overall 5‐year survival for death from disease only was 92.8%. Overall survival by tumour size alone showed that women with tumours less than 2 cm had a 98.3% 5‐year survival compared to 83.4% for tumour size greater than 2 cm. Irrespective of tumour size, those that had no evidence of lymphovascular space invasion had a 100% 5‐year survival.ConclusionOur preliminary data supports the oncological safety of RRH in a selective cohort of patients with stage 1b1 CC.

Laparoscopic and Robotic Surgery for Endometrial and Cervical Cancer

“…In the LACC trial, each centre only contributed a small number of patients to the MIS group, leading to the surgical quality being questioned [93]. The oncological safety of robotic radical hysterectomy has been reported in retrospective reviews [90,94], particularly in those with tumour size <2 cm [95,96] and no evidence of lymphovascular space invasion [97]. The extent to which the mode of MIS has an effect on oncological outcomes will hopefully be answered by the ongoing 'Robot-assisted Approach to Cervical Cancer (RACC) trial, an international multi-centre, open-label randomised controlled trial [98].…”

An optimized robotic surgical technique for cervical cancer: investigating whether the use of the pulling robotic arm has better surgical outcomes

“…Moreover, another retrospective study came up with the opposite conclusion, arguing that OS was higher in the MIS group compared with the ARH ( 13 ). Although the above studies cannot be of equivalent quality to the LACC trial, it is believed that MIS for cervical cancer in selected cases (tumor diameters less than 2 cm) will not affect the oncologic outcomes ( 14 , 15 ).…”